{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,5]],"date-time":"2022-04-05T01:37:19Z","timestamp":1649122639336},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2008,7,1]],"date-time":"2008-07-01T00:00:00Z","timestamp":1214870400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Cardiol Rep"],"published-print":{"date-parts":[[2008,7]]},"DOI":"10.1007\/s11886-008-0050-0","type":"journal-article","created":{"date-parts":[[2008,10,15]],"date-time":"2008-10-15T03:05:20Z","timestamp":1224039920000},"page":"312-318","source":"Crossref","is-referenced-by-count":1,"title":["Which heparin and how much?"],"prefix":"10.1007","volume":"10","author":[{"given":"Peter E.","family":"Ruchin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marino","family":"Labinaz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2008,10,16]]},"reference":[{"key":"50_CR1","unstructured":"MIMS Point of Care database, CMP Medica Australia 2007: Heparin sodium injection. http:\/\/proxy8.use.hcn.com.au\/ifmx-nsapi\/mims-data\/?MIval=2MIMS_abbr_pi&product_code=311&product_name=Heparin+Sodium+Injection . Enoxaparinsodium. http:\/\/proxy8.use.hcn.com.au\/ifmx-nsapi\/mims-data\/?MIval=2MIMS_abbr_pi&product_code=2658&product_name=Clexane+and+Clexane+Forte . http:\/\/www.mims.com.au. . Accessed February 2008."},{"key":"50_CR2","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1161\/01.CIR.89.3.1449","volume":"89","author":"J. Hirsh","year":"1994","unstructured":"Hirsh J, Fuster V: Guide to anticoagulant therapy. Part 1: heparin. American Heart Association. Circulation 1994, 89:1449\u20131468.","journal-title":"Circulation"},{"key":"50_CR3","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s11239-006-9049-9","volume":"23","author":"J.D. Rich","year":"2007","unstructured":"Rich JD, Maraganore JM, Young E, et al.: Heparin resistance in acute coronary syndromes. J Thromb Thrombolysis 2007, 23:93\u2013100.","journal-title":"J Thromb Thrombolysis"},{"key":"50_CR4","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1161\/01.CIR.97.3.251","volume":"97","author":"Z. Xiao","year":"1998","unstructured":"Xiao Z, Theroux P: Platelet activation with unfractionated heparin at therapeutic concentrations and comparisons with a low-molecular-weight heparin and with a direct thrombin inhibitor. Circulation 1998, 97:251\u2013256.","journal-title":"Circulation"},{"key":"50_CR5","unstructured":"University of Washington Medical Center Anticoagulation Services: Guidelines for dosing and monitoring enoxaparin. http:\/\/www.uwmcacc.org\/Enoxaparin.html . Accessed February 2008."},{"key":"50_CR6","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1016\/S0140-6736(81)92399-0","volume":"1","author":"A.M. Telford","year":"1981","unstructured":"Telford AM, Wilson C: Trial of heparin versus atenolol in prevention of myocardial infarction in intermediate coronary syndrome. Lancet 1981, 1:1225\u20131228.","journal-title":"Lancet"},{"key":"50_CR7","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1056\/NEJM198810273191701","volume":"319","author":"P. Th\u00e9roux","year":"1988","unstructured":"Th\u00e9roux P, Ouimet H, McCans J, et al.: Aspirin, heparin, or both to treat acute unstable angina. N Engl J Med 1988, 319:1105\u20131111.","journal-title":"N Engl J Med"},{"key":"50_CR8","doi-asserted-by":"crossref","unstructured":"Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease. The RISC Group [no authors listed]. Lancet 1990, 336:827\u2013830.","DOI":"10.1016\/0140-6736(90)92336-G"},{"key":"50_CR9","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1016\/S0140-6736(95)91990-2","volume":"345","author":"G.G. NeriSerneri","year":"1995","unstructured":"NeriSerneri GG, Modesti PA, Gensini GF, et al.: Randomised comparison of subcutaneous heparin, intravenous heparin, and aspirin in unstable angina. Studio Epoorine Sottocutanea nell\u2019Angina Instobile (SESAIR) Refrattorie Group. Lancet 1995, 345:1201\u20131204. (Published erratum appears in Lancet 1995, 346:130.)","journal-title":"Lancet"},{"issue":"5Pt1","key":"50_CR10","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1161\/01.CIR.88.5.2045","volume":"88","author":"P. Th\u00e9roux","year":"1993","unstructured":"Th\u00e9roux P, Waters D, Qiu S, et al.: Aspirin versus heparin to prevent myocardial infarction during the acute phase of unstable angina. Circulation 1993, 88(5 Pt 1):2045\u20132048.","journal-title":"Circulation"},{"key":"50_CR11","unstructured":"Braunwald E, Antman EM, Beasley JW, et al.: ACC\/AHA 2002 Guideline Update for the Management of Patients With Unstable Angina and Non-ST-Segment Elevation Myocardial Infarction: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina). Available at http:\/\/www.acc.org\/qualityandscience\/clinical\/guidelines\/unstable\/update_index.htm . Accessed February 2008."},{"key":"50_CR12","doi-asserted-by":"crossref","first-page":"II383","DOI":"10.1161\/CIRCULATIONAHA.107.710913","volume":"116","author":"C. Melloni","year":"2007","unstructured":"Melloni C, Alexander KP, Chen AY, et al.: Unfractionated heparin dosing and major bleeding in non-ST-segment elevation acute coronary syndromes [abstract 1800]. Circulation 2007, 116:II383.","journal-title":"Circulation"},{"key":"50_CR13","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1056\/NEJM199207163270301","volume":"327","author":"P. Th\u00e9roux","year":"1992","unstructured":"Th\u00e9roux P, Waters D, Lam J, et al.: Reactivation of unstable angina after the discontinuation of heparin. N Engl J Med 1992, 327:141\u2013145.","journal-title":"N Engl J Med"},{"key":"50_CR14","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1016\/j.jacc.2003.05.014","volume":"42","author":"N.R. Bijsterveld","year":"2003","unstructured":"Bijsterveld NR, Peters RJ, Murphy SA, et al.: Recurrent cardiac ischemic events early after discontinuation of short-term heparin treatment in acute coronary syndromes: results from the Thrombolysis in Myocardial Infarction (TIMI) 11B and Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events (ESSENCE) studies. J Am Coll Cardiol 2003, 42:2083\u20132089.","journal-title":"J Am Coll Cardiol"},{"key":"50_CR15","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1161\/01.CIR.100.15.1593","volume":"100","author":"E.M. Antman","year":"1999","unstructured":"Antman EM, McCabe CH, Gurfinkel EP, et al.: Enoxaparin prevents death and cardiac ischemic events in unstable angina\/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial. Circulation 1999, 100:1593\u20131601.","journal-title":"Circulation"},{"key":"50_CR16","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/S0735-1097(01)01825-3","volume":"39","author":"N.R. Bijsterveld","year":"2002","unstructured":"Bijsterveld NR, Moons AH, Meijers JC, et al.: Rebound thrombin generation after heparin therapy in unstable angina. A randomized comparison between unfractionated and low-molecular-weight heparin. J Am Coll Cardiol 2002, 39:811\u2013817.","journal-title":"J Am Coll Cardiol"},{"key":"50_CR17","doi-asserted-by":"crossref","unstructured":"Dose-ranging trial of enoxaparin for unstable angina: results of TIMI 11A. The Thrombolysis in Myocardial Infarction (TIMI) 11A Trial Investigators [no authors listed]. J Am Coll Cardiol 1997, 29:1474\u20131482.","DOI":"10.1016\/S0735-1097(97)00094-6"},{"key":"50_CR18","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/S0735-1097(00)00808-1","volume":"36","author":"S.G. Goodman","year":"2000","unstructured":"Goodman SG, Cohen M, Bigonzi F, et al.: Randomized trial of low molecular weight heparin (enoxaparin) versus unfractionated heparin for unstable coronary artery disease: one-year results of the ESSENCE Study. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q Wave Coronary Events. J Am Coll Cardiol 2000, 36:693\u2013698.","journal-title":"J Am Coll Cardiol"},{"key":"50_CR19","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1161\/01.CIR.97.17.1702","volume":"97","author":"D.B. Mark","year":"1998","unstructured":"Mark DB, Cowper PA, Berkowitz SD, et al.: Economic assessment of low-molecular-weight heparin (enoxaparin) versus unfractionated heparin in acute coronary syndrome patients: results from the ESSENCE randomized trial. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q wave Coronary Events [unstable angina or non-Q-wave myocardial infarction]. Circulation 1998, 97:1702\u20131707.","journal-title":"Circulation"},{"key":"50_CR20","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1001\/jama.292.1.55","volume":"292","author":"M.A. Blazing","year":"2004","unstructured":"Blazing MA, de Lemos JA, White HD, et al.: Safety and efficacy of enoxaparin vs unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes who receive tirofiban and aspirin: a randomized controlled trial. A to Z Investigators. JAMA 2004, 292:55\u201364. (Published erratum appears in JAMA 2004, 292:1178.)","journal-title":"JAMA"},{"key":"50_CR21","first-page":"45","volume":"292","author":"J.J. Ferguson","year":"2004","unstructured":"Ferguson JJ, Califf RM, Antman EM, et al.: Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial. SYNERGY Trial Investigators. JAMA 2004, 292:45\u201354.","journal-title":"JAMA"},{"key":"50_CR22","doi-asserted-by":"crossref","unstructured":"Low-molecular-weight heparin during instability in coronary artery disease, Fragmin during Instability in Coronary Artery Disease (FRISC). FRISC study group [no authros listed]. Lancet 1996, 347:561\u2013568.","DOI":"10.1016\/S0140-6736(96)91270-2"},{"key":"50_CR23","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1161\/01.CIR.96.1.61","volume":"96","author":"W. Klein","year":"1997","unstructured":"Klein W, Buchwald A, Hillis SE, et al.: Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease. Fragmin in unstable coronary artery disease study (FRIC). Circulation 1997, 96:61\u201368. (Published erratum appears in Circulation 1998, 97:413.)","journal-title":"Circulation"},{"key":"50_CR24","doi-asserted-by":"crossref","unstructured":"Long-term low-molecular-mass heparin in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. FRagmin and Fast Revascularisation during InStability in Coronary artery disease (FRISC). FRISC Investigators [no authors listed]. Lancet 1999, 354:701\u2013707. (Published erratum appears in Lancet 1999, 354:1478.)","DOI":"10.1016\/S0140-6736(99)07350-X"},{"key":"50_CR25","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1093\/eurheartj\/ehm224","volume":"28","author":"S.A. Murphy","year":"2007","unstructured":"Murphy SA, Gibson CM, Morrow DA, et al.: Efficacy and safety of the low-molecular weight heparin enoxaparin compared with unfractionated heparin across the acute coronary syndrome spectrum: a meta-analysis. Eur Heart J 2007, 28:2077\u20132086.","journal-title":"Eur Heart J"},{"key":"50_CR26","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1056\/NEJMoa055443","volume":"354","author":"S. Yusuf","year":"2006","unstructured":"Yusuf S, Mehta SR, Chrolavicus S, et al.: Comparison of fondaparinux and enoxaparin in acute coronary syndromes. Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators. N Engl J Med 2006, 354:1464\u20131476.","journal-title":"N Engl J Med"},{"key":"50_CR27","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1016\/j.jacc.2007.07.042","volume":"50","author":"S.R. Mehta","year":"2007","unstructured":"Mehta SR, Granger CB, Eikelboom JW, et al.: Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: results from the OASIS-5 trial. J Am Coll Cardiol 2007, 50:1742\u20131751.","journal-title":"J Am Coll Cardiol"},{"key":"50_CR28","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1056\/NEJMoa062437","volume":"355","author":"G.W. Stone","year":"2006","unstructured":"Stone GW, McLaurin BT, Cox DA, et al.: Bivalirudin for patients with acute coronary syndromes. ACUITY Investigators. N Engl J Med 2006, 355:2203\u20132216.","journal-title":"N Engl J Med"},{"key":"50_CR29","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.jacc.2007.10.001","volume":"51","author":"E.M. Antman","year":"2008","unstructured":"Antman EM, Hand M, Armstrong PW, et al.: 2007 focused update of the ACC\/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines. Canadian Cardiovascular Society; American Academy of Family Physicians; American College of Cardiology; American Heart Association. J Am Coll Cardiol 2008, 51:210\u2013247.","journal-title":"J Am Coll Cardiol"},{"key":"50_CR30","doi-asserted-by":"crossref","first-page":"3855","DOI":"10.1161\/CIRCULATIONAHA.105.573550","volume":"112","author":"J.W. Eikelboom","year":"2005","unstructured":"Eikelboom JW, Quinlan DJ, Mehta SR, et al.: Unfractionated and low-molecular-weight heparin as adjuncts to thrombolysis in aspirin-treated patients with ST-elevation acute myocardial infarction: a meta-analysis of the randomized trials. Circulation 2005, 112:3855\u20133867.","journal-title":"Circulation"},{"key":"50_CR31","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1056\/NEJMoa060898","volume":"354","author":"E.M. Antman","year":"2006","unstructured":"Antman EM, Morrow DA, McCabe CH, et al.: Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction. ExTRACT-TIMI 25 Investigators. N Engl J Med 2006, 354:1477\u20131488.","journal-title":"N Engl J Med"},{"key":"50_CR32","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1093\/eurheartj\/ehi181","volume":"26","author":"B.K. Nallamothu","year":"2005","unstructured":"Nallamothu BK, Bates ER, Hochman JS, et al.: Prognostic implication of activated partial thromboplastin time after reteplase or half-dose reteplase plus abciximab: results from the GUSTO-V trial. Eur Heart J 2005, 26:1506\u20131512.","journal-title":"Eur Heart J"},{"key":"50_CR33","doi-asserted-by":"crossref","first-page":"3846","DOI":"10.1161\/CIRCULATIONAHA.105.595397","volume":"112","author":"M.S. Sabatine","year":"2005","unstructured":"Sabatine MS, Morrow DA, Montalescot G, et al.: Angiographic and clinical outcomes in patients receiving low-molecular-weight heparin versus unfractionated heparin in ST-elevation myocardial infarction treated with fibrinolytics in the CLARITY-TIMI 28 Trial. Clopidogrel as Adjunctive Reperfusion Therapy (CLARITY)-Thrombolysis in Myocardial Infarction (TIMI) 28 Investigators. Circulation 2005, 112:3846\u20133854.","journal-title":"Circulation"},{"key":"50_CR34","doi-asserted-by":"crossref","first-page":"2249","DOI":"10.1016\/j.jacc.2006.12.049","volume":"49","author":"K.A. Fox","year":"2007","unstructured":"Fox KA, Antman EM, Montalescot G, et al.: The impact of renal dysfunction on outcomes in the ExTRACT-TIMI 25 trial. J Am Coll Cardiol 2007, 49:2249\u20132255.","journal-title":"J Am Coll Cardiol"},{"key":"50_CR35","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/S0140-6736(06)68148-8","volume":"367","author":"E.C. Keeley","year":"2006","unstructured":"Keeley EC, Boura JA, Grines CL: Comparison of primary and facilitated percutaneous coronary interventions for ST-elevation myocardial infarction: quantitative review of randomised trials. Lancet 2006, 367:579\u2013588 (Published erratum appears in Lancet 2006, 367:1656.)","journal-title":"Lancet"},{"issue":"3Suppl","key":"50_CR36","first-page":"576S","volume":"126","author":"J.J. Popma","year":"2004","unstructured":"Popma JJ, Berger P, Ohman EM, et al.: Antithrombotic therapy during percutaneous coronary intervention: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Ghest 2004, 126(3 Suppl):576S\u2013599S.","journal-title":"Ghest"},{"key":"50_CR37","doi-asserted-by":"crossref","unstructured":"Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trial. ESPRIT Investigators. Enhanced Suppression of the Platelet IIb\/IIIa Receptor with Integrilin Therapy. Lancet 2000, 356:2037\u20132044. (Published erratum appears in Lancet 2001, 357:1370.)","DOI":"10.1016\/S0140-6736(00)03400-0"},{"key":"50_CR38","doi-asserted-by":"crossref","unstructured":"Platelet glycoprotein IIb\/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. The EPILOG Investigators. N Engl J Med 1997, 336:1689\u20131696.","DOI":"10.1056\/NEJM199706123362401"},{"key":"50_CR39","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1161\/01.CIR.0000139868.53594.24","volume":"110","author":"S.J. Brener","year":"2004","unstructured":"Brener SJ, Moliterno DJ, Lincoff AM, et al.: Relationship between activated clotting time and ischemic or hemorhagic complications: analysis of 4 recent randomized clinical trials of percutaneous coronary intervention. Circulation 2004, 110:994\u2013998.","journal-title":"Circulation"},{"key":"50_CR40","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1002\/ccd.21062","volume":"70","author":"R.C. Welsh","year":"2007","unstructured":"Welsh RC, Gordon P, Westerhout CM, et al.: A novel enoxaparin regime for ST elevation myocardial infarction patients undergoing primary percutaneous coronary intervention: a WEST sub-study. Catheter Cardiovasc Interv 2007, 70:341\u2013348.","journal-title":"Catheter Cardiovasc Interv"},{"key":"50_CR41","first-page":"116","volume":"8","author":"H.M. Medina","year":"2007","unstructured":"Medina HM, Cheong BYC, O\u2019Meallie L, et al.: The safety and efficacy of enoxaparin as antithrombin therapy during primary percutaneous coronary intervention for ST-elevation myocardial infarction [abstract]. Cardiovasc Reveasc Med 2007, 8:116\u2013154.","journal-title":"Cardiovasc Reveasc Med"},{"key":"50_CR42","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1001\/jama.295.13.joc60038","volume":"295","author":"S. Yusuf","year":"2006","unstructured":"Yusuf S, Mehta SR, Chrolavicius S, et al.: Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial. JAMA 2006, 295:1519\u20131530.","journal-title":"JAMA"}],"container-title":["Current Cardiology Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11886-008-0050-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11886-008-0050-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11886-008-0050-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T19:56:08Z","timestamp":1559418968000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11886-008-0050-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,7]]},"references-count":42,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2008,7]]}},"alternative-id":["50"],"URL":"https:\/\/doi.org\/10.1007\/s11886-008-0050-0","relation":{},"ISSN":["1523-3782","1534-3170"],"issn-type":[{"value":"1523-3782","type":"print"},{"value":"1534-3170","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,7]]}}}